---
layout: default
title: Aztreonam
parent: 僅模型預測 (L5)
nav_order: 26
evidence_level: L5
indication_count: 10
---

# Aztreonam
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# AZTREONAM: Drug Repurposing Evaluation Report

## One-Sentence Summary

Aztreonam is a monobactam-class antibiotic used for treating serious gram-negative bacterial infections. The TxGNN model **has not generated any predicted new indications** for this drug, and the evidence pack contains significant data gaps that prevent a full evaluation.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available in current evidence pack (known: gram-negative bacterial infections) |
| Predicted New Indication | None (no TxGNN predictions available) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — No predictions or supporting studies |
| Taiwan Market Status | ✗ Not marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

## Why is This Prediction Reasonable?

Currently, the TxGNN model has not generated any repurposing predictions for Aztreonam. Without a predicted new indication, mechanism-based reasoning cannot be performed at this time.

Aztreonam (DrugBank ID: DB00355) is the only commercially available monobactam antibiotic. It works by inhibiting bacterial cell wall synthesis through binding to penicillin-binding protein 3 (PBP-3), and is uniquely selective for aerobic gram-negative organisms. Detailed mechanism of action data was not available in this evidence pack (flagged as data gap DG002), though the drug's mechanism is well-characterized in the literature.

Because the predicted indications array is empty, this candidate cannot proceed to further evaluation stages. The absence of predictions may be due to insufficient knowledge graph connectivity for this drug, or the model may not have identified any high-confidence repurposing opportunities above the scoring threshold.

## Clinical Trial Evidence

Currently no related clinical trials registered — no predicted indication available for evidence mapping.

## Literature Evidence

Currently no related literature available — no predicted indication available for evidence mapping.

## Taiwan Market Information

Aztreonam currently holds **no valid marketing authorizations** (藥證) from the TFDA. The drug is classified as **not marketed (未上市)** in Taiwan.

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| — | — | — | No authorizations on record |

## Safety Considerations

> Please refer to the package insert for safety information.
>
> All safety data fields (key warnings, contraindications, and drug-drug interactions) returned as data gaps in the current evidence pack. The TFDA package insert query returned 1 result but the structured safety data was not extracted (see data gap DG001, severity: **Blocking**).

## Data Gaps Summary

The following critical data gaps were identified and must be resolved before re-evaluation:

| Gap ID | Item | Severity | Impact | Remediation |
|--------|------|----------|--------|-------------|
| DG001 | TFDA Package Insert Warnings/Contraindications | **Blocking** | Cannot enter S1 safety preliminary assessment | Download and parse package insert PDF from TFDA website |
| DG002 | Mechanism of Action (MOA) | High | Affects mechanism-indication relevance analysis | Query DrugBank API |

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
No TxGNN repurposing predictions exist for Aztreonam, and the drug is not marketed in Taiwan (0 authorizations). Combined with blocking-level data gaps in safety information, there is insufficient basis to proceed with any repurposing evaluation.

**To proceed, the following is needed:**
- Resolution of **DG001** (Blocking): Extract TFDA package insert warnings and contraindications
- Resolution of **DG002** (High): Obtain detailed MOA data from DrugBank API
- Re-run TxGNN prediction pipeline to confirm whether predictions can be generated for this drug
- If predictions remain empty, investigate whether the knowledge graph contains sufficient Aztreonam-related edges (targets, pathways, phenotypes) for meaningful prediction
- Verify whether Aztreonam's absence from the Taiwan market is relevant to the study scope, or if international market data (e.g., FDA, EMA) should be incorporated as supplementary evidence
## Ansvarsfriskrivning

Detta innehåll är endast avsett för forskningsändamål och utgör inte medicinsk rådgivning.
Klinisk validering krävs före klinisk tillämpning.

---

